Elevated Immunoglobulin G4 Levels in Patients with Thyroid Eye Disease and Their Clinical Implications

Huijing Ye, Wei Xiao, Rongxin Chen, Ping Zhang, Lijuan Tang, Jingqiao Chen, Te Zhang, Xian Ji, Lu Shi, and Huasheng Yang

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China

Elevated immunoglobulin G4-related disease (IgG4-RD) has recently been increasingly recognized as a multisystem fibro-inflammatory disorder characterized by typical immunoglobulin G4 (IgG4)-positive lymphoplasmacytic infiltration. Ophthalmic involvement is common in IgG4-RD and has always been described as orbital inflammatory disease or a pseudotumor that can affect nearly every orbital structure. Thyroid eye disease (TED) is one of the most common orbital inflammatory diseases. Studies of elevated serum IgG4 levels in the presence of TED have suggested that IgG4 levels are associated with the development of TED in patients with Graves’ disease (GD). Additionally, in an American study of a small group of patients with TED (24 cases), 20.8% of patients demonstrated serum IgG4 levels consistent with IgG4-RD without any additional systemic disease, and Irwin et al reported a patient with TED with significant IgG4 staining in the levator palpebrae superioris. The above findings suggest that there may be a possible subtype of patients with TED with elevated pathological or serological IgG4 levels. However, studies based on a large number of cases with IgG4 levels in the TED subgroup remain limited. Moreover, data regarding patients with TED with both pathological and serological IgG4 levels measured have not been previously reported.

To determine whether there is a subtype of patients with TED with elevated IgG4 levels and identify the clinicopathological features of this subtype, we prospectively and simultaneously assessed the levels of serum IgG4 and IgG4-positive plasma cells in orbital tissues obtained in 185 consecutive patients with TED and assessed the possible association between IgG4 levels and TED.

Keywords: thyroid eye disease, immunoglobulin G4, clinicopathological features

Subjects and Methods

Patients

This prospective observational cohort study was performed in consecutive patients with TED who underwent orbital decompression and were simultaneously assessed for blood and orbital adipose tissue between October 2017 and December 2018. The diagnosis of TED was based on their clinical, laboratory, and imaging findings. The exclusion criteria of the study were as follows: (1) prior surgery on the operative eye, (2) steroid or immunosuppressive agent use within the last 6 months, (3) pregnancy or lactation, (4) active infection, (5) with any kind of immunodeficiency disorder, and (6) evidence of any unresolved medical problem that can affect IgG4 levels. Approval was obtained in accordance with the Declaration of Helsinki and the Ethics Committee of Zhongshan Ophthalmic Center, Sun Yat-sen University. Written informed consent was obtained from each patient.
Laboratory Evaluation

Serum levels of total triiodothyronine (TT3), total thyroxine (TT4), free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), thyrotropin receptor antibody (TRAb), and thyroid peroxidase antibody (TPOAb) were measured by electrochemiluminescent immunoassays (Roche, Rotkreuz, Switzerland). Antithyroglobulin antibody (TgAb) levels were measured with a chemiluminescent immunoassay (Architect i2000; Abbot Japan, Tokyo, Japan). Serum IgG4 and complement C3 and C4 concentrations were measured by turbidimetric assay (SRL, Tokyo, Japan).

Histopathological Evaluation and Immunohistochemistry

After surgical resection of the orbital adipose tissue, formalin-fixed and paraffin-embedded sections were subjected to hematoxylin-eosin (HE) and immunohistochemical staining. All sections of surgical specimens were double-blind reviewed by two senior pathologists who evaluated the histopathological findings. The intensities of fibrosis and lymphocytic infiltration were semiquantified as 3+: severe, 2+: moderate, 1+: mild, or 0+: negative.

Immunohistochemical staining for IgG4 (mouse monoclonal antibody, MRQ-44; Gene Tech, Shanghai, China), IgG (rabbit monoclonal antibody; Gene Tech, CD20 (mouse monoclonal antibody; Gene Tech), and CD3 (mouse monoclonal antibody; Gene Tech) were performed. For each section, the mean numbers of IgG4-positive and IgG-positive cells were counted in three high-power fields (HPFs), the counts in the region with the highest density of immunostained cells were calculated, and the IgG4/IgG ratio was recorded. The area of each high-power region was approximately 0.24 mm² (Olympus BX50 microscope).

Diagnostic Criteria for the IgG4-positive and IgG4-negative Groups

According to the diagnostic criteria for IgG4-related ophthalmic disease (ROD) defined in 2014,8 patients with TED were categorized into the IgG4-positive group if they fulfilled either of the following criteria: (1) histopathological IgG4-positive indicating a histopathological examination showing an IgG4/IgG-positive cell ratio > 40% or an IgG4-positive plasma cell density ≥ 50/HPF, or (2) serum IgG4-positive indicating a blood test showing elevated serum IgG4 levels (≥ 135 mg/dl). In particular, diagnosis was classified as “definitive” when (1) and (2) were satisfied; “probable” when only (1) was satisfied; and “possible” when only (2) was satisfied. Patients who did not meet any of these requirements were considered IgG4-negative TED (IgG4-negative group).

Ophthalmological Evaluation

The severity of TED was assessed according to the European Group on Graves’ Orbitopathy (EUGOGO) criteria, which was categorized as mild, moderate to severe, or sight threatening.2 In addition, TED activity was assessed by the EUGOGO seven-item clinical activity score (CAS) criteria, in which CAS scores of 3 or higher are defined as active stage, whereas those with CAS scores below 3 are defined as stable stage.10

Treatment

The enrolled patients underwent orbital decompression, which was conducted by the same experienced doctor, followed by intravenous glucocorticoid administration. Importantly, after surgery, patients with sight-threatening TED or active eye disease received methylprednisolone pulse therapy (MPT) at a dose of 1 g of methylprednisolone per day for three consecutive days, which has been proven effective for improving visual function and relieving clinical symptoms compared with MPT alone in a recent study,11 whereas all other patients received methylprednisolone at a dose of 80 mg per day for three consecutive days. Prednisone was subsequently taken orally at a dose of 30 mg/day and gradually reduced to decrease the active immune attack stimulated by surgical stress and postoperative chemosis.12,13 The clinical features of the patients, including best corrected visual acuity (BCVA) and CAS before surgery, were analyzed.

Statistical Analysis

Statistical analyses were performed using SPSS version 22.0 (SPSS, Chicago, IL, USA). The means and standard deviations (SDs) of the quantitative variables were calculated. The paired t-test or analysis of variance (ANOVA) with Bonferroni’s test for comparisons was used to analyze the quantitative variables when the assumptions of normality and homogeneity of variance were satisfied; otherwise, the Mann–Whitney U-test or Kruskal–Wallis test were used. Differences between rates or ratios were determined using the x² test. Logistic regression analysis was used to estimate the influence of variables on CAS in patients with TED. Two-tailed Spearman’s rank correlation analysis was used to evaluate the correlations between two variables. Any P value < 0.05 was considered to be statistically significant.

RESULTS

Of the 185 total patients who agreed to participate in the study, 64 patients (34.6%) were included in the IgG4-positive group (histopathological or serum IgG4 positive), including 15 patients (8.1%), 27 patients (14.6%), and 22 patients (11.9%) who were allocated to the definitive (both histopathological and serum IgG4-positive), probable (only histopathological IgG4-positive), and possible (only serum IgG4-positive) groups, respectively, and 121 patients (65.4%) were included in the IgG4-negative group. The median age was 49.4 (range, 17.0–76.0) years. There were 100 male (54.1%) and 85 female patients (45.9%). All patients had normal TT3, TT4, FT3, and FT4 levels before surgery. In addition, IgG4-RD was not observed in other organs during the general examination.

Baseline Characteristics of Patients With IgG4-positive and IgG4-negative TED

The baseline characteristics of the IgG4-positive and IgG4-negative patients with TED were compared and are summarized in Table 1. Although sex, laterality, and smoking history were not different among the four groups, patients were older in the IgG4-positive group than in the IgG4-negative group (P = 0.008). Specifically, patients were oldest in the possible IgG4-positive group (P = 0.021), and were also
### Table 1. Baseline Characteristics of IgG4-Positive and IgG4-Negative Patients with TED

| Variable                             | Definitive (n = 15) | Probable (n = 27) | Possible (n = 22) | All (n = 64) | IgG4-negative (n = 121) | P1    | P2    | P3 | P4 | P5 |
|--------------------------------------|---------------------|-------------------|-------------------|--------------|------------------------|-------|-------|----|----|----|
| **Sex, Male:Female**                 | 10:5                | 14:13             | 13:9              | 37:27        | 63:58                  | 0.285 | 0.984 | 0.544 | 0.456 | 0.698 |
| **Age at diagnosis, y**              | 53.40 ± 12.11       | 50.44 ± 9.29      | 55.91 ± 10.03     | 53.02 ± 10.37| 47.45 ± 13.46          | 1.000 | 1.000 | **0.021** | **0.008** | **0.025** |
| **Laterality, bilateral:unilateral**| 14:1                | 26:1              | 22:9              | 62:2         | 109:12                 | 1.000 | 0.512 | 0.260 | 0.171 | 0.341 |
| **Smoking history, n (%)**           | 8 (53.3)            | 10 (37.0)         | 9 (40.9)          | 27 (42.2)    | 35 (28.9)              | 0.105 | 0.407 | 0.263 | 0.069 | 0.214 |
| **Severity (moderate-to-severe: sight-threatening)** |                      |                   |                   |              |                        |       |       |     |     |     |
| Pre-operative CAS                    | 2.53 ± 1.73         | 2.04 ± 1.53       | 1.68 ± 1.49       | 2.03 ± 1.57  | 1.05 ± 1.16            | 0.003 | 0.007 | 0.318 | <0.001 | <0.001 |
| Pre-operative BCVA logMAR            | 0.56 ± 0.78         | 0.59 ± 0.73       | 0.88 ± 0.76       | 0.68 ± 0.75  | 0.43 ± 0.60            | 1.000 | 1.000 | **0.023** | **0.026** | **0.023** |
| Duration of TED, mo                  | 42.33 ± 64.11       | 22.37 ± 23.67     | 19.23 ± 23.91     | 25.97 ± 37.68| 31.18 ± 31.84          | 0.987 | 0.499 | 0.259 | 0.322 | 0.087 |
| History of steroid use, n (%)        | 12 (80.0)           | 19 (70.4)         | 18 (81.8)         | 49 (76.6)    | 88 (72.7)              | 0.770 | 0.805 | 0.370 | 0.571 | 0.737 |
| Initial thyroid function             |                     |                   |                   |              |                        |       |       |     |     |     |
| Hyperthyroidism, n (%)               | 12 (80.0)           | 26 (96.3)         | 18 (81.8)         | 56 (87.5)    | 103 (85.1)             | 0.889 | 0.211 | 0.941 | 0.658 | 0.360 |
| Hypothyroidism, n (%)                | 0 (0.0)             | 1 (3.7)           | 2 (9.1)           | 3 (4.7)      | 5 (4.1)                | 1.000 | 1.000 | 0.649 | 1.000 | 0.589 |
| Euthyroidism, n (%)                  | 3 (20.0)            | 0 (0.0)           | 2 (9.1)           | 5 (7.8)      | 13 (10.7)             | 0.532 | 0.159 | 1.000 | 0.522 | 0.183 |
| Hashimoto's thyroiditis, n (%)       | 1 (6.7)             | 0 (0.0)           | 0 (0.0)           | 1 (1.6)      | 0 (0.0)               | 0.110 | NA    | NA   | 0.346 | 0.081 |
| Duration of thyroid disease, mo      | 63.67 ± 66.62       | 34.11 ± 28.47     | 40.05 ± 59.96     | 42.14 ± 50.10| 53.81 ± 60.38          | 1.000 | 0.657 | 1.000 | 0.207 | 0.278 |
| I-131 therapy history, n (%)         | 2 (13.3)            | 4 (14.8)          | 4 (18.2)          | 10 (15.6)    | 29 (24.0)              | 0.549 | 0.302 | 0.554 | 0.186 | 0.618 |
| Hypothyroidism after I-131 therapy, n (%) | 1 (50.0)          | 3 (75.0)          | 3 (75.0)          | 7 (70.0)     | 14 (48.3)              | 1.000 | 0.639 | 0.639 | 0.412 | 0.678 |

**P1**, definitive IgG4-positive versus IgG4-negative; **P2**, probable IgG4-positive versus IgG4-negative; **P3**, possible IgG4-positive versus IgG4-negative; **P4**, all IgG4-positive versus IgG4-negative; **P5**, definitive IgG4-positive versus probable IgG4-positive versus possible IgG4-positive versus IgG4-negative.

Data are shown as the means plus/minus SDs. IgG4, immunoglobulin G4; TED, thyroid eye disease; CAS, clinical activity score; BCVA, best corrected visual acuity; NA, not applicable. Significant P values are shown with bold characters.
older in the definitive and probable IgG4-positive groups, although these differences were not significant.

Pre-operative CAS tended to be elevated as a function of advancement in patients with IgG4-positive TED (definitive IgG4-positive versus probable IgG4-positive versus possible IgG4-positive versus IgG4-negative, 2.53 ± 1.73 vs. 2.04 ± 1.53 vs. 1.68 ± 1.49 vs. 1.05 ± 1.16; \( P < 0.001 \)). When patients with TED were classified as having inactive (\( n = 146; 78.9\% \)) or active (\( n = 39; 21.1\% \)) ophthalmopathy status, the proportion of active patients was higher in the IgG4-positive group than in the IgG4-negative group (39.1% vs. 11.6%; \( P < 0.001 \)).

In addition, IgG4-positive patients with TED had worse BCVA than IgG4-negative patients with TED (\( P = 0.026 \)). Specifically, possible IgG4-positive patients with TED had worst BCVA (\( P = 0.023 \)), and BCVA was also worse in the definitive and probable IgG4-positive subgroups than in the IgG4-negative group, although these differences were not significant. Moreover, disease was most severe in the possible IgG4-positive group (\( P = 0.002 \)). The four groups did not differ regarding steroid history, initial thyroid function, I-131 therapy history, hypothyroidism after I-131 therapy, and duration of TED or thyroid disease.

**Laboratory and Pathological Characteristics of Patients With IgG4-positive and IgG4-negative TED**

Table 2 shows a comparison of the laboratory and pathological findings obtained in patients with IgG4-positive and IgG4-negative TED. Histopathological IgG4 levels tended to be elevated as a function of advancement in patients with IgG4-positive TED (definitive IgG4-positive versus probable IgG4-positive versus possible IgG4-positive versus IgG4-negative, 10.47 ± 14.94 vs. 3.33 ± 4.84 vs. 1.18 ± 1.82 vs. 0.66 ± 0.94; \( P < 0.001 \)). In addition, IgG4/IgG ratios were higher in the IgG4-positive groups than in the IgG4-negative group, with both \( P < 0.001 \) in definitive and probable IgG4-positive subgroups, and was also higher in the possible IgG4-positive group, although this difference was not significant. Furthermore, definitive and possible IgG4-positive patients with TED had higher serum IgG4 levels (\( P < 0.001 \) and < 0.001, respectively) than IgG4-negative patients with TED. In addition, serum IgG4 levels were positively correlated with histopathological IgG4 and the IgG4/IgG ratio in all 185 patients (Pearson \( r = 0.186, P = 0.011 \); \( r = 0.262, P < 0.001 \)).

![figure](https://example.com/figure.png)

**Figure.** Histopathology images of IgG4-positive patients with TED. (A) HE staining (×40 magnification), (B) HE staining (×200 magnification), (C) immunohistochemical staining for IgG4 (×400 magnification), (D) immunohistochemical staining for IgG, (×400 magnification), (E) immunohistochemical staining for CD20 (×200 magnification), and (F) immunohistochemical staining for CD3 (×200 magnification). HE, hematoxylin and eosin.

**IgG4 Subtype is an Independent Factor Associated with Clinical Activity in Patients With TED**

To identify whether IgG4 is an independent factor associated with higher clinical activity in patients with TED, we performed logistic regression analysis, including factors potentially related factors with clinical activity (Table 3). In the univariate analysis, age at diagnosis (\( P = 0.024 \)) and IgG4 subtype (definitive IgG4-positive, \( P < 0.001 \); probable IgG4-positive, \( P < 0.001 \)) were significantly associated with active stage (CAS ≥ 3) in patients with TED. In the
Table 2. Laboratory and Pathological Characteristics of IgG4-Positive and IgG4-Negative Patients with TED

| Variable                  | Definitive (n = 15) | Probable (n = 27) | Possible (n = 22) | All (n = 64) | IgG4-negative TED (n = 121) | P1   | P2   | P3   | P4   | P5   |
|---------------------------|---------------------|-------------------|-------------------|-------------|-----------------------------|------|------|------|------|------|
| Serum IgG4, g/l           | 2.44 ± 1.20         | 0.67 ± 0.32       | 3.16 ± 3.90       | 1.94 ± 2.59 | 0.58 ± 0.33                 | <0.001 | 1.000 | <0.001 | <0.001 | <0.001 |
| Serum C3, g/l             | 1.15 ± 0.18         | 1.20 ± 0.54       | 1.23 ± 0.17       | 1.20 ± 0.16 | 1.24 ± 0.22                 | 0.804 | 1.000 | 1.000 | 0.215 | 0.449 |
| Serum C4, g/l             | 0.36 ± 0.25         | 0.33 ± 0.12       | 0.27 ± 0.78       | 0.32 ± 0.15 | 0.30 ± 0.13                 | 0.860 | 0.277 | 0.412 | 0.587 | 0.670 |
| TT3, nmol/l               | 1.63 ± 0.38         | 1.80 ± 0.78       | 1.71 ± 0.35       | 1.73 ± 0.57 | 1.75 ± 0.47                 | 1.000 | 1.000 | 1.000 | 0.798 | 0.762 |
| TT4, nmol/l               | 80.79 ± 35.95       | 94.78 ± 27.85     | 99.18 ± 30.43     | 93.15 ± 31.06 | 97.63 ± 27.94               | 0.245 | 1.000 | 1.000 | 0.330 | 0.211 |
| FT3, pmol/l               | 4.37 ± 1.12         | 5.11 ± 1.84       | 5.01 ± 0.82       | 4.90 ± 1.41 | 5.09 ± 1.27                 | 0.287 | 1.000 | 1.000 | 0.349 | 0.256 |
| FT4, pmol/l               | 14.24 ± 6.43        | 15.53 ± 5.05      | 16.03 ± 4.58      | 15.40 ± 5.21 | 16.40 ± 4.89                | 0.709 | 1.000 | 1.000 | 0.198 | 0.421 |
| TSH, μIU/ml               | 3.55 ± 4.89         | 3.67 ± 6.79       | 2.51 ± 3.79       | 3.25 ± 5.43 | 4.41 ± 8.29                | 1.000 | 1.000 | 1.000 | 0.312 | 0.718 |
| TRAb, IU/l                | 17.75 ± 21.41       | 17.66 ± 31.52     | 21.02 ± 44.55     | 18.93 ± 34.66 | 8.97 ± 13.97               | 0.039 | 0.063 | 0.550 | 0.031 | 0.103 |
| TgAb, IU/ml               | 338.80 ± 838.15     | 145.10 ± 367.94   | 256.70 ± 645.32   | 225.10 ± 604.38 | 163.41 ± 463.91             | 1.000 | 1.000 | 1.000 | 0.452 | 0.614 |
| TPOAb, IU/ml              | 140.74 ± 209.66     | 28.78 ± 27.48     | 166.45 ± 218.84   | 108.03 ± 178.75 | 69.25 ± 124.96             | 0.631 | 1.000 | 0.092 | 0.065 | 0.059 |
| No. of IgG4 (+) cells/HPF | 10.47 ± 14.94       | 3.33 ± 4.84       | 1.18 ± 1.82       | 4.27 ± 8.56 | 0.66 ± 0.94                 | <0.001 | <0.001 | 1.000 | <0.001 | <0.001 |
| No. of IgG4 (+) cells/HPF | 15.87 ± 21.80       | 4.70 ± 8.88       | 3.91 ± 3.24       | 7.05 ± 12.88 | 4.33 ± 3.08                | 0.053 | 0.085 | 0.559 | 0.548 | 0.054 |
| IgG4 (+)/IgG4 (-) cells (%) | 81.11 ± 22.91      | 88.27 ± 23.49     | 25.00 ± 37.80     | 64.85 ± 40.90 | 14.04 ± 29.75               | <0.001 | <0.001 | 0.666 | <0.001 | <0.001 |

Lymphocytic infiltrate, -1/+2+/3+

Degree of fibrosis, -1/+2+/3+

CD20+ lymphocytic infiltrate, -1/+2+/3+

CD3+ lymphocytic infiltrate, -1/+2+/3+

P1, definitive IgG4-positive versus IgG4-negative; P2, probable IgG4-positive versus IgG4-negative; P3, possible IgG4-positive versus IgG4-negative; P4, all IgG4-positive versus IgG4-negative; P5, definitive IgG4-positive versus probable IgG4-positive versus possible IgG4-positive versus IgG4-negative.

Data are shown as the means plus/minus SDs. IgG4, immunoglobulin G4; TED, thyroid eye disease; HPF, high-power field.

Significant P values are shown with bold characters.
multivariate analysis, after adjusting for age, sex, smoking history, status of I-131 therapy, and steroid therapy in the multivariate analysis, the definite and probable IgG4 subtypes were independently associated with the active stage in patients with TED (both $P < 0.001$, odds ratio [OR] = 6.83; 95% confidence interval [CI] = 2.07–22.6 in the definitive IgG4-positive group; OR = 5.83; 95% CI = 2.19–15.5 in the probable IgG4-positive group).

**DISCUSSION**

The purpose of this study was to demonstrate that there is a subset of patients with TED with elevated IgG4 levels that meets the IgG4-RD criteria but shows no findings indicating systemic IgG4-RD. TED and IgG4-RD are both autoimmune fibrous inflammatory diseases in which Th2 lymphocytes play a dominant role in their development. Therefore, some scholars have recently suggested that there are certain correlations between TED and IgG4-RD, including evaluated serum or histopathological IgG4 levels. However, the data from a large number of patients with TED with both pathological and serological IgG4 levels remain limited. Our aim was to prospectively gather valid data from patients with TED undergoing orbital decompression to determine whether there is a subpopulation of patients with TED with elevated IgG4 levels and to identify the clinicopathological features of this subtype.

In the current study, a novel subgroup of patients with TED undergoing orbital decompression with elevated IgG4 levels was identified (34.6% of overall patients). Although only 8.1% of patients with TED were both histopathological and serum IgG4 positive, patients with either histopathological or serum IgG4 positivity still presented a series of unique clinicopathologic features compared with IgG4-negative patients with TED. They were older and had higher CAS, worse BCVA, a higher histopathological IgG4 count, a higher IgG4/IgG ratio, and more lymphocytic infiltrates than IgG4-negative patients. The age of onset in patients with TED who were IgG4 positive was 53.02 years, which was similar to that in patients with IgG4-RD (mean age 55.5 years) and slightly younger than that in other patients with IgG4-RD (mean age 58 years). Moreover, our study suggests that IgG4-positive patients with TED are older than IgG4-negative patients with TED (47.45 years), similar to what has been found in IgG4-positive patients with GD. However, in a report from Korea, there was no difference in the age of onset of TED between the IgG4-negative and IgG4-positive subtypes when differentiated by serology, which may be related to the fact that all of their subjects were patients with GD and in a younger age group (37.20 years). In fact, IgG4 levels do not increase with age, suggesting that some unknown factor may be responsible for the abnormal expression of IgG4.

We found that the IgG4-positive subtype was an independent factor associated with the active stage in patients with TED. There were more active patients and patients with a higher CAS in the IgG4-positive group than in the IgG4-negative group in our study, consistent with the conclusion presented in a previous Korean study. In addition, our results show that IgG4-positive patients had more severe disease and worse BCVA than IgG4-negative patients. According to the natural course of TED, the early stage of TED is progressive and reflects the process of autoimmunity, with activity peaking at 13 to 24 months. Then, the inflammatory response gradually subsides to the plateau stage, with increased intramuscular fatty degeneration and fibrosis. This suggests that IgG4 may play an important role in the early onset of TED and that high IgG4 activity predicts the development of more severe muscle lesions and orbital fibrosis and even a worse visual prognosis. Moreover, in our study, the IgG4-positive group had higher levels of TRAb, TgAb, and TPOAb, and more orbital tissue lymphocytic infiltration than the IgG4-negative group, indicating that IgG4 is an asymmetric, bispecific antibody that is closely related to the activity of the disease from the perspective of autoimmune diseases caused by thyroid destruction.

Similar to the research of a small group of patients with TED (24 cases) in America, in our study of 185 Chinese patients, 37 patients (20.0%) with TED had elevated serum IgG4 levels. Furthermore, 42 patients (22.7%) with TED had an elevated histopathological IgG4/IgG ratio. In fact, similar to our study, other studies have found that the serum level of IgG4 is often but not always elevated in patients with IgG4-RD. Approximately only two-thirds of patients with IgG4-RD have elevated serum IgG4 levels, and only 23% of pathologically identified patients with IgG4-positive IgG4-RD have elevated serum IgG4 levels. The relative dys-synchrony of serum and pathologic IgG4 may provide two possible explanations for the overabundance of IgG4 antibodies: tissue-destructive immunoglobulins and the response to an unknown primary inflammatory stimulus. However, we found that patients with either histopathological or serum IgG4 positivity still presented a series of unique clinicopathologic features compared with IgG4-negative patients with TED, indicating a more active and severe subtype.
Immunoglobulin G4 Levels in Thyroid Eye Disease

Some limitations in this study need to be noted. We investigated only patients with TED undergoing orbital decompression, which involved a large number of patients with moderate-to-severe and even sight-threatening disease. As reported before, the female-to-male ratio in these patients was significantly lower than that in Caucasian patients with TED and even overall patients with TED. Moreover, it is difficult to make comparison with other studies of patients with mild TED.

In conclusion, in the current study, we propose clinical, serological, and histopathological characteristics of the IgG4 subtype of patients with TED and confirm that elevated IgG4 levels are common in patients with TED and should be given consideration. IgG4-positive patients with TED are characterized by older age, higher activity, and more severe disease. IgG4-positive subtype was an independent factor associated with the active stage in patients with TED, indicating that IgG4 may also play an important role in the pathogenesis of TED.

Acknowledgments

Supported by the National Natural Science Foundation of China (81700875; 81870689; and 81670887) and the Sun Yat-Sen University Clinical Research 5010 Program, China (2014014). The authors alone are responsible for the content and writing of the paper.

Disclosure: H. Ye, None; W. Xiao, None; R. Chen, None; P. Zhang, None; L. Tang, None; J. Chen, None; T. Zhang, None; X. Ji, None; L. Shi, None; H. Yang, None

References

1. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366:539–551.
2. Wallace ZS, Deshpande V, Stone JH. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review. Semin Arthritis Rheum. 2014;43:806–817.
3. Yu SH, Kang JG, Kim CS, et al. Clinical implications of immunoglobulin G4 to Graves' ophthalmopathy. Thyroid. 2017;27:1185–1193.
4. Bozkirli E, Bakiner OS, Ersozlu Bozkirli ED, et al. Serum immunoglobulin G4 levels are elevated in patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2015;83:962–967.
5. Kashani I, Rajak SN, Kearney DJ, Andrew NH, Selva D. IgG4 staining in thyroid eye disease. Ophthaml Plast Reconstr Surg. 2017;33:5183–5185.
6. Sy A, Silkiss RZ. Serum total IgG and IgG4 levels in thyroid eye disease. Int Med Case Rep J. 2016;9:325–328.
7. Bartley GB, Gorman CA. Diagnostic criteria for Graves’ ophthalmopathy. Am J Ophthalmol. 1995;119:792–795.
8. Goto H, Takahira M, Azumi A. Japanese Study Group for Ig GROD. Diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Ophthalmol. 2015;59:1–7.
9. Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5:9–26.
10. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–285.
11. Xu J, Ye H, Chen G, Chen J, Chen R, Yang H. The therapeutic effect of combination of orbital decompression surgery and methylprednisolone pulse therapy on patients with bilateral dysthyroid optic neuropathy. J Ophthalmol. 2020;2020:9323450.
12. Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves’ ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf). 2005;63:323–328.
13. Takahashi Y, Kang H, Kakizaki H. Lower incidence of chemosis with the Berke incision approach versus the swinging eyelid approach for deep lateral orbital wall decompression. J Plast Surg Hand Surg. 2016;50:15–18.
14. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–738.
15. Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobulin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007;45:1536–1546.
16. Khandji J, Campbell AA, Callahan AB, Sirinek P, Kazim M. IgG4-related orbital disease masquerading as thyroid eye disease, vice versa, or both? Orbit. 2018;37:239–242.
17. Kubota T, Moritani S, Terasaki H. Ocular adnexal IgG4-related lymphoplasmaclitic inflammatory disorder and Graves ophthalmopathy. Arch Ophthalmol. 2011;129:818–829; author reply 829.
18. Andrew N, Kearney D, Selva D. IgG4-related orbital disease: a meta-analysis and review. Acta Ophthalmol. 2013;91:694–700.
19. Lee MJ, Kim N, Choe JY, et al. Clinicopathological analysis of ocular adnexal extranodal marginal zone B-cell lymphoma with IgG4-positive cells. PLoS One. 2015;10:e0131458.
20. Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012;22:1–14.
21. Takeshima K, Inaba H, Furukawa Y, et al. Serum immunoglobulin G4 levels in patients with Graves’ disease and their clinical implications. Thyroid. 2014;24:736–743.
22. Martin CS, Sirbu AE, Betivoiu MA, Florea S, Barbu CG, Fica SV. Serum immunoglobulin G4 levels and Graves’ disease phenotype. Endocr Pract. 2017;23:478–484.
23. Rundle FF, Wilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci. 1945;5:177–194.
24. Potgiesser PW, de Win M, Wiersinga WM, Mourits MP. Natural course of mild graves orbitopathy: increase of orbital fat but decrease of muscle volume with increased muscle fatty degeneration during a 4-year follow-up. Ophthaml Plast Reconstr Surg. 2019;35:456–460.
25. Menconi F, Profilo MA, Leo M, et al. Spontaneous improvement of untreated mild Graves’ ophthalmopathy: Rundle’s curve revisited. Thyroid. 2014;24:60–66.
26. Vaglio A, Zwerina J. IgG4-related disease. N Engl J Med. 2012;366:1646; author reply 1647.
27. Wallace ZS, Deshpande V, Mattoo H, et al. IgG4-related disease in patients with idiopathic orbital inflammation syndrome: data from the French SIOI prospective cohort. Acta Ophthalmol. 2019;97:e648–e656.
28. Adad S, Martin A, Heran F, et al. IgG4-related disease in patients with idiopathic orbital inflammation syndrome: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 2015;67:2466–2475.
29. Li Q, Ye H, Ding Y, et al. Clinical characteristics of moderate-to-severe thyroid associated orbitopathy in 354 Chinese cases. PLoS One. 2017;12:e0176064.